Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial
{{output}}
Background: Immune thrombocytopenia is an autoimmune bleeding disorder. Daratumumab, a human monoclonal antibody targeting CD38 glycoprotein, is currently under clinical investigation as a potential therapy for autoimmune disease... ...
